Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib, have been proven to efficiently inhibit the proliferation of a subset of non small-cell lung cancers (NSCLC). Unfortunately, the majority of NSCLC expressing wild type EGFR is primarily resistant to EGFR-TKI...
Enregistré dans:
Auteurs principaux: | Anke Bill, Anton Schmitz, Katharina König, Lukas C Heukamp, Jeffrey S Hannam, Michael Famulok |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2012
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/abcd96ca8a6243b0bebc9a26e3465d5a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Glycyrol Alone or in Combination with Gefitinib Is Effective against Gefitinib-Resistant HCC827GR Lung Cancer Cells
par: Shuang Zhao, et autres
Publié: (2021) -
Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
par: Gang Chen, et autres
Publié: (2013) -
Management of patients with advanced non-small cell lung cancer: role of gefitinib
par: Vamsidhar Velcheti, et autres
Publié: (2010) -
Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy
par: Sugiura Y, et autres
Publié: (2013) -
Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer
par: Chuncao Xu, et autres
Publié: (2021)